MedTrace Logo

Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)

NCT07632898 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 484

Last updated 2026-06-08

No results posted yet for this study

Summary

This is a multicenter, open-label extension (OLE), single-arm study designed to assess the long-term safety and tolerability of oral IKT-001 administered once daily.

Conditions

  • Pulmonary Arterial Hypertension (PAH)

Interventions

DRUG

IKT-001

IKT-001 tablets for PO administration

Sponsors & Collaborators

  • Inhibikase Therapeutics

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-23
Primary Completion
2030-06-30
Completion
2030-12-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07632898 on ClinicalTrials.gov